Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression

IntroductionReceptor tyrosine kinases have been extensively studied owing to their frequently abnormal activation in the development and progression of human cancers. Platelet-derived growth factor receptors (PDGFRs) are receptors with intrinsic tyrosine kinase activity that regulate several functions in normal cells and are widely expressed in a variety of malignancies. After the demonstration that gastrointestinal stromal tumours without c-Kit mutations harbour PDGFR-α-activating mutations and that PDGFR-α is also a therapeutic target for imatinib mesylate, the interest for this receptor has increased considerably. Because breast cancer is one of the most frequent neoplasias in women worldwide, and only one study has reported PDGFR-α expression in breast carcinomas, the aim of this work was to investigate the potential significance of PDGFR-α expression in invasive mammary carcinomas.MethodsWe used immunohistochemistry to detect PDGFR-α overexpression on a series of 181 formalin-fixed paraffin-embedded invasive ductal breast carcinomas and in two breast cancer cell lines: MCF-7 and HS578T. We associated its expression with known prognostic factors and we also performed polymerase chain reaction–single-stranded conformational polymorphism and direct sequencing to screen for PDGFR-α mutations.ResultsPDGFR-α expression was observed in 39.2% of the breast carcinomas and showed an association with lymph node metastasis (P = 0.0079), HER-2 expression (P = 0.0265) and Bcl2 expression (P = 0.0121). A correlation was also found with the expression of platelet-derived growth factor A (PDGF-A; P = 0.0194). The two cell lines tested did not express PDGFR-α. Screening for mutations revealed alterations in the PDGFR-α gene at the following locations: 2500A→G, 2529T→A and 2472C→T in exon 18 and 1701G→A in exon 12. We also found an intronic insertion IVS17-50insA at exon 18 in all sequenced cases. None of these genetic alterations was correlated with PDGFR-α expression. The cell lines did not reveal any alterations in the PDGFR-α gene sequence.ConclusionPDGFR-α is expressed in invasive breast carcinomas and is associated with biological aggressiveness. The genetic alterations described were not correlated with protein expression, but other mechanisms such as gene amplification or constitutive activation of a signalling pathway inducing this receptor could still sustain PDGFR-α as a potential therapeutic target.

[1]  N. Davidson,et al.  Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Shiekhattar,et al.  Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. , 1995, Genomics.

[3]  B. Lloveras,et al.  Bcl‐2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer , 2000, International journal of cancer.

[4]  M. Pfaltz,et al.  Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors , 2002, Genes, chromosomes & cancer.

[5]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[6]  H. Joensuu,et al.  Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma , 2004, British Journal of Cancer.

[7]  G. Divine,et al.  The association of HER-2/neu amplification with breast cancer recurrence. , 2000, Archives of surgery.

[8]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[9]  K. Franssila,et al.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Mol,et al.  Switching on kinases: oncogenic activation of BRAF and the PDGFR family , 2004, Nature Reviews Cancer.

[11]  Erwin G. Van Meir,et al.  Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). , 2003, International journal of oncology.

[12]  P. V. van Diest,et al.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops , 1998, The Journal of pathology.

[13]  Kylie L. Gorringe,et al.  Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers : a new approach for the molecular analysis of paraffin-embedded cancer tissue. , 2001, The American journal of pathology.

[14]  A. Ostman PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. , 2004, Cytokine & growth factor reviews.

[15]  J. Bonner,et al.  Regulation of PDGF and its receptors in fibrotic diseases. , 2004, Cytokine & growth factor reviews.

[16]  A. Gown,et al.  Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. , 1995, Cancer research.

[17]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[18]  Andrius Kazlauskas,et al.  PDGF signaling in cells and mice. , 2004, Cytokine & growth factor reviews.

[19]  Shaomeng Wang,et al.  Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. , 2003, Seminars in oncology.

[20]  M. Marberger,et al.  Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. , 2003, American journal of clinical pathology.

[21]  E. Raines PDGF and cardiovascular disease. , 2004, Cytokine & growth factor reviews.

[22]  C. Betsholtz,et al.  Developmental roles of platelet‐derived growth factors , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  L. Pilarski,et al.  The malignant clone in Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[24]  À. Sierra,et al.  Inhibition of apoptosis in human breast cancer cells: Role in tumor progression to the metastatic state , 2002, International journal of cancer.

[25]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[26]  F. Milanezi,et al.  c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? , 2004, Journal of Clinical Pathology.

[27]  M. Hung,et al.  Dysregulation of cellular signaling by HER2/neu in breast cancer. , 2003, Seminars in oncology.

[28]  M. Oka,et al.  Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. , 2003, Cancer genetics and cytogenetics.

[29]  A. Gown,et al.  Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. , 1995, Cancer research.